Merck to acquire OncoImmune
KENILWORTH, N.J. — Merck and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments
